HALOZYME THERAPEUTICS, INC. stock analysis

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeut

Ticker: HALO
Exchange: Nasdaq
Sector: Health Care
Industry: Pharmaceuticals

Market evidence and data freshness

The public preview recorded HALOZYME THERAPEUTICS, INC. at 125.205 USD on 2026-11-05T18:34:02.000Z and marked the quote as delayed. This observation is not a trading signal.

Available price history spans 2026-05-11 through 2026-11-03 across 123 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

What should I review before buying HALOZYME THERAPEUTICS, INC. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

Inside the full analysis

Valuation
Growth
Financial health
Ownership
Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.